🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

307 results for “Disc Medicine” Clear

  1. Pharmacokinetic study of minocycline in patients with nontuberculous mycobacterial disease

    Disc Medicine

    Nontuberculous mycobacterial disease

    phase 1 other active

    1 trial

  2. Phase 0 trial of CBD in recurrent glioblastoma patients

    Disc Medicine

    Glioblastoma

    phase 1 other active

    1 trial

  3. Phase I study of 225Ac-PSMA I&T in prostate cancer

    Disc Medicine

    metastatic prostate cancer

    phase 1 other active

    1 trial

  4. Pilot Study on Subcutaneously Administered Immunotherapy for the Treatment of Cervical Cancer

    Disc Medicine

    Cervical Cancer

    phase 1 other active

    1 trial

  5. RESTART; Autologous Transplantation of Adult Salivary Gland Stem Cells to Restore Submandibular Gland Function after Radiotherapy

    Disc Medicine

    Patients operated with curative intend for head and neck cancer with an indication for bilateral postoperative radiotherapy, with or without chemotherapy.

    phase 1 other active

    1 trial

  6. Repurposed Drugs in Research and Cancer Clinical Trials. The ReDiReCCT trial Vemurafenib

    Disc Medicine

    Glioma

    phase 1 other active

    1 trial

  7. STRATIFY; Near-infrared fluorescence molecular imaging of adalimumab-800CW to elucidate the drug distribution throughout inflamed tissue in inflammatory bowel disease and rheumatoid arthritis

    Disc Medicine

    Crohn's disease, Spondyloarthritis, Rheumatoid arthritis, Ulcerative colitis

    phase 1 other active

    1 trial

  8. Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM

    Disc Medicine

    Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM)

    phase 1 other active

    1 trial

  9. Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma

    Disc Medicine

    Patients with stage II-IV high risk diffuse large B-cell lymphoma, defined as international prognostic index > 2, Lymphoma

    phase 1 other active

    1 trial

  10. The detection of tumor-associated fibrosis in colorectal peritoneal metastases by FAPI-PET (TROMPET)

    Disc Medicine

    Metastatic colorectal cancer

    phase 1 other active

    1 trial

  11. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  12. 18F-Canagliflozin, Invokana 300 mg film-coated tablets

    Disc Medicine

    Chronic Kidney disease

    approved small molecule active

    1 trial

  13. ACETYLSALICYLIC ACID , CLOPIDOGREL , RIVAROXABAN

    Disc Medicine

    Peripheral Arterial Disease

    approved small molecule active

    1 trial

  14. ADALIMUMAB , INFLIXIMAB

    Disc Medicine

    Crohn's disease Ulcerative colitis

    approved small molecule active

    1 trial

  15. ALITRETINOIN, CICLOSPORIN, ALITRETINOIN, CICLOSPORIN

    Disc Medicine

    Hand eczema

    approved small molecule active

    1 trial

  16. AMINOHIPPURIC ACID , IOTALAMATE MEGLUMINE, Adrenaline CF 1 mg/ml, oplossing voor injectie, OMNIPAQUE 300 mg I/ml, Tavegyl 1 mg/ml, oplossing voor injectie, SODIUM IOTALAMATE (125I)

    Disc Medicine

    Chronic Kidney Disease Kidney Failure

    approved small molecule active

    1 trial

  17. ARIPIPRAZOLE , RISPERIDONE

    Disc Medicine

    Autism spectrum disorder

    approved small molecule active

    1 trial

  18. ATORVASTATIN, PLACEBO

    Disc Medicine

    Atherosclerosis

    approved small molecule active

    1 trial

  19. Acetylsalicylzuur Aurobindo cardio 80 mg, tabletten.

    Disc Medicine

    ST elevation myocardial infarction (STEMI)

    approved small molecule active

    1 trial

  20. Alecensa 150 mg hard capsules

    Disc Medicine

    ALK positive non-small cell lung cancer

    approved small molecule active

    1 trial

  21. Amoxicillin 500 mg film-coated tablets, Placebo amoxicillin capsules 500mg

    Disc Medicine

    non-specific low back pain

    approved small molecule active

    1 trial

  22. Atropine 1.0% eye drops solution

    Disc Medicine

    Myopia

    approved small molecule active

    1 trial

  23. Avastin 25 mg/ml concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Disc Medicine

    Metastatic cervical cancer

    approved small molecule active

    1 trial

  24. BECLOMETASONE , FLUTICASONE , BUDESONIDE , SALBUTAMOL

    Disc Medicine

    Episodic expiratory wheezing

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources